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Abstract
Background Smoking is a major risk factor for bladder cancer, but the relationship between smoking cessation after initial 
treatment and bladder cancer recurrence has been investigated less frequently and not prospectively yet.
Methods 722 non-muscle-invasive bladder cancer (NMIBC) patients (pTa, pT1, and CIS) from the prospective Bladder 
Cancer Prognosis Programme (BCPP) cohort, selected in the UK between 2005 and 2011, provided complete data on smok-
ing behavior before and up to 5 years after diagnosis. The impact of smoking behavior on NMIBC recurrence was explored 
by multivariable Cox regression models investigating time-to-first NMIBC recurrence.
Results Over a median follow-up period of 4.21 years, 403 pathologically confirmed NMIBC recurrences occurred in 210 
patients. Only 25 current smokers at diagnosis quit smoking (14%) during follow-up and smoking cessation after diagnosis 
did not decrease risk of recurrence compared to continuing smokers (p = 0.352).
Conclusions Although quitting smoking after diagnosis might reduce the risk of recurrence based on retrospective evidence, 
this is not confirmed in this prospective study because the number of NMIBC patients quitting smoking before their first 
recurrence was too low. Nevertheless, this indicates an important role for urologists and other health care professionals in 
promoting smoking cessation in NMIBC.
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Introduction
Bladder cancer (BC) is estimated to be the ninth most fre-
quent cancer worldwide with approximately 400,000 newly 
diagnosed cases per year [1]. Compared to other cancers, 
mortality rates are generally lower for BC [1] since the 
majority of BCs diagnosed are non-muscle-invasive blad-
der cancers (NMIBC) [2]. However, NMIBC often recurs 
[3] and has a risk of progressing to muscle-invasive bladder 
cancer (MIBC) [4], events which impact on the quality of 
life of the patient [5] and generate high disease management 
costs [6].
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Although smoking is an established risk factor for BC, its 
effects has been less frequently investigated in relation to BC 
prognosis [7–10]. Although many studies investigated effec-
tiveness of treatment for NMIBC and MIBC with regard to 
recurrence, progression, and mortality, most studies did not 
investigate the effect of smoking or other factors modifi-
able by patients on BC prognosis [11]. Nevertheless, the 
number of studies also reporting hazard ratios (HRs) for 
BC recurrence by smoking status at diagnosis has increased 
recently and the current body of evidence consistently shows 
that there is a small association between smoking and BC 
recurrence when comparing current smokers to never smok-
ers at diagnosis [10, 12]. However, the impact of smoking 
cessation after BC diagnosis on recurrence and mortality 
has not yet been quantified prospectively [13]. Studies have 
investigated the impact of smoking cessation within 1 year 
after diagnosis on BC recurrence, showing a slight decrease 
in risk of recurrence [14, 15], and one study indicates no 
effect of quitting after diagnosis on overall or bladder can-
cer-specific mortality [16].
The Bladder Cancer Prognosis Programme (BCPP) fol-
lowed up BC patients for 5 years post-diagnosis and investi-
gated changes in smoking behavior in relation to the course 
of the disease [17]. The principal aim of this study was to 
investigate whether smoking cessation post-diagnosis and 
smoking behavior pre-diagnosis influences BC recurrence.
Methods
The Bladder Cancer Prognosis programme
This study was conducted within the framework of the West 
Midlands Bladder Cancer Prognosis Programme (BCPP), a 
cohort study in the United Kingdom. Details of the study are 
described elsewhere [17]. In brief, individuals were included 
between December 2005 and October 2011 after referral to 
participating urology centers due to symptoms suspicious 
of BC and followed for a maximum of 5 years from diag-
nosis. Patients with previous cancer of the urethra, bladder, 
ureter, or renal pelvis within the last decade were excluded. 
The study was ethically approved (06/MRE04/65) and all 
participants gave written informed consent.
Data collection
At or around time of diagnosis, trained research nurses used 
semi-structured face-to-face interviews and questionnaires 
to collect data on social support, health-related quality of 
life, sociodemographics, medical history, and health-related 
behaviors including smoking behavior. Variables on smok-
ing behavior included current smoking status (never, former, 
current), duration (years of smoking), intensity (cigarettes 
per day), smoking cessation (in years), and tobacco type 
(filter, non-filter, or rolled cigarettes, cigar, or pipe). Monthly 
smoking status was also assessed retrospectively by postal 
questionnaires that were sent out to participants yearly until 
the end of follow-up.
Smoking status at diagnosis and during follow‑up
A combined smoking status variable was created indicat-
ing continuing smokers, former smokers who consistently 
abstained, never smokers, former smokers who started 
smoking again, and current smokers who quit smoking 
post-diagnosis. Patients were considered quitters when they 
abstained consistently, so smokers who quit for 3 months 
and then started again were considered as continuing smok-
ers. Furthermore, for each participant that reported smoking 
cessation during follow-up, it was confirmed whether this 
occurred before or after their first recurrence. If patients quit 
smoking after their first recurrence, they were considered as 
continuing smokers in the time-to-first recurrence analysis.
Population at risk
Of the 1,550 cases who agreed to participate, 231 were 
subsequently identified as not having BC. Patients who 
presented with MIBC (n = 275) disease at diagnosis were 
excluded from analysis because they are fundamentally dif-
ferent from NMIBC with regard to recurrence. Patients with 
squamous or adenocarcinomas of non-urothelial origin or 
with bladder cancer as secondary carcinoma were excluded 
(n = 41). In addition to patients presenting with Ta and 
T1 tumors, carcinoma in situ (CIS) tumors were included 
(n = 16) since they have an increased risk of recurrence [18]. 
In total, 846 (84%) of these patients had provided data on 
smoking behavior at diagnosis and during follow-up and 
remained under follow-up within the cohort study. Of the 
included 846 NMIBC patients, there were 116 patients with 
unknown recurrent tumor stage. These 116 unconfirmed 
events were excluded for other analyses as well as 8 cases 
who had radiotherapy (on suspicion of being MIBC cases) 
resulting in a NMIBC patient population at risk of recur-
rence of 722.
No systematic guidance or tools were provided to enable 
patients to quit smoking after diagnosis, so care as usual was 
applied by all participating urologists.
Statistical analysis
BC recurrence was defined as a new tumor that was at the 
same stage as the primary tumor (Ta or T1) but also when 
a primary Ta patient had a T1 recurrence. Patients that pro-
gressed from T1 to T2 disease were not counted as a recur-
rence but as a progression event. Unfortunately, there were 
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not enough events to also consider biological progression 
within this sample of NMIBC patients, as defined in the 
BCPP cohort [19]. Therefore, this study only focussed on 
confirmed recurrence events and patients who experienced 
a progression event were censored in the survival analysis 
when the progression event was diagnosed.
The impact of smoking behavior on BC recurrence was 
explored by Cox regression models—with time since initial 
transurethral resection of the bladder tumor (TURBT) as 
the time-metric—investigating possible differences in like-
lihood of a first recurrence. We explored two different Cox 
regression models: one adjusted for age at diagnosis and sex 
(model 1) and one additionally adjusted for BC stage, grade, 
tumor size, and number of tumors at diagnosis (model 2). 
This set of confounders was chosen since they are mark-
ers of NMIBC prognosis and are factors that contribute to 
European Association of Urology (EAU) risk stratification 
for clinical decisions [20]. Moreover, they are potentially 
associated with smoking behavior at diagnosis [21]. Conse-
quently, conditional risk set modeling was applied to inves-
tigate time between multiple recurrent events and analysis 
time was reset at each event [22]. For this analysis, re-resec-
tion of tumors was added to model 2 as a confounder. The 
proportional hazards assumption was checked in all models 
using Schoenfeld residuals. Cumulative incidence functions 
(CIF) corrected for competing risks (death) were made [23].
Furthermore, the differences in mean number of recur-
rences over 5 years between never smokers, former smokers, 
and continuing smokers were compared using a multivari-
able ANOVA model correcting for pairwise comparisons 
using Tukey’s HSD. There were not enough BC-related 
death events (45) or confirmed progression events (19) 
to allow for separate analyses. A similarly low number of 
progression events has been observed in a large (n = 718) 
NMIBC patient sample before [24].
NMIBC patients who died before the end of follow-up 
(n = 157) were censored at time of death, and patients who 
underwent cystectomy (n = 15) were censored at the date 
of cystectomy (13). Other patients were considered lost to 
follow-up when the date on which patients were last seen in 
the hospital for bladder cancer-related therapy or the date on 
which they filled in their last follow-up questionnaire was 
before the end of follow-up (5 years).
Results
Number of recurrences and characteristics 
of population at risk
All 722 patients at risk of recurrence were followed over 
a median period of 4.21 years (IQR 2.64–5.00 years). The 
majority of patients (506, 70%) were followed for at least 
3 years. Over this period of follow-up, 210 NMIBC patients 
experienced at least one confirmed recurrence event. These 
210 NMIBC patients accumulated a total of 403 confirmed 
recurrence events in the cohort.
Most cases were male (79%) and around the age of 70 
(Table 1). Furthermore, continuing smokers seemed to be 
underrepresented in the low EAU risk group (12%), those 
who quit smoking seemed more likely to be younger and 
female, and continuing smokers seemed more likely to 
present with multiple tumors at diagnosis (Table 1). In 
the multivariate models, 26 patients were not included in 
the analysis due to missing data on age (n = 7), number of 
tumors at diagnosis (n = 15), and tumor size (n = 4). Because 
participants were recruited from multiple centers, patients 
were treated by multiple urologists with different individual 
thresholds to perform certain therapies. Therefore, not all 
patients were treated exactly according to the EAU guide-
lines [20], which is often the case in actual clinical practice 
[25].
Associations between smoking behavior pre‑ 
and post‑diagnosis and BC recurrence
Although HR estimates for smoking cessation pre-diag-
nosis indicated a protective association with BC recur-
rence, the p for linear trend was not statistically significant 
(ptrend = 0.126) and therefore the association cannot be con-
sidered as strong (Table 2). No association between smok-
ing status and risk of recurrence was observed in the mul-
tivariable model (Table 2). Interestingly, when compared 
to continuing smokers (HR 1.04, 95% CI 0.65–1.66), HRs 
were similar for those who quit smoking (p = 0.352) and 
former smokers who started again post-diagnosis (p = 0.431) 
(Table 2). Additionally, the cumulative incidence function 
shows that cumulative incidence of BC recurrence was low-
est for former smokers and never smokers (Fig. 1).
Only 25 smokers (14%) of the 174 current smokers origi-
nally recorded at diagnosis quit smoking at any point during 
follow-up. Three quitters were excluded for full analysis for 
not having information on their date last seen and another 
five had missing data regarding the invasiveness of their 
recurrent events. Of the 480 former smokers at diagnosis, 
172 (36%) started smoking (any form of tobacco) again post-
diagnosis in all included 846 NMIBC patients.
Exposure to environmental tobacco smoke during child-
hood (HR 1.17, 95% CI 0.81–1.68) or adulthood (HR 1.02, 
95% CI 0.76–1.36) did not seem to have any impact on time-
to-first recurrence (Table 2).
Table 3 shows HRs for time-to-first recurrence by smok-
ing intensity, duration, and pack-years. No linear trends were 
observed although the highest categories showed the highest 
point estimates for both smoking intensity and pack-years. 
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Table 1  Patient characteristics at diagnosis and number of recurrences over 5 years for 722 NMIBC patients treated with transurethral resection 
by smoking category
*Kruskal–Wallis test for continuous and Chi-square test for categorical variables
Overall (n = 722) Combined smoking status
Never 
smoker 
(n = 103)
Former 
smoker 
(n = 266)
Continu-
ing smoker 
(n = 186)
Former smoker who 
started again (n = 150)
Quitters after 
diagnosis 
(n = 17)
p value*
Age in years < 0.001
 Median (25th–
75th percentile)
71 (63–77) 72 (61–79) 72 (67–79) 67 (57–74) 72 (64–77) 62 (56–67)
Sex < 0.001
 Male 573 (79%) 63 (61%) 231 (87%) 139 (75%) 129 (86%) 11 (65%)
 Female 149 (21%) 40 (39%) 35 (13%) 47 (25%) 21 (14%) 6 (35%)
EAU risk group < 0.001
 Low 128 (18%) 28 (27%) 71 (27%) 23 (12%) 4 (3%) 2 (12%)
 Intermediate 383(53%) 50 (49%) 131 (49%) 97 (52%) 91 (61%) 14 (82%)
 High 211 (29%) 25 (24%) 64 (24%) 66 (36%) 55 (37%) 1 (6%)
Number of tumors < 0.001
 1 429 (61%) 70 (70%) 179 (69%) 100 (55%) 69 (46%) 11 (65%)
 2–7 258 (36%) 27 (27%) 74 (28%) 76 (42%) 75 (50%) 6 (35%)
 ≥ 8 22 (3%) 3 (3%) 8 (3%) 6 (3%) 5 (3%) 0 (-)
Tumor size 0.068
 < 3 cm 445 (63%) 68 (68%) 174 (67%) 105 (58%) 85 (57%) 13 (76%)
 ≥ 3 cm 260 (37%) 32 (32%) 84 (33%) 77 (42%) 63 (43%) 4 (24%)
Grade 0.001
 1 212 (30%) 34 (34%) 99 (38%) 51 (28%) 26 (17%) 2 (13%)
 2 257 (36%) 34 (34%) 75 (28%) 73 (40%) 66 (44%) 9 (56%)
 3 245 (34%) 33 (33%) 90 (34%) 60 (32%) 57 (38%) 5 (31%)
Stage 0.590
 pTa 476 (66%) 68 (66%) 184 (69%) 115 (62%) 95 (63%) 14 (82%)
 pT1 239 (33%) 35 (34%) 79 (30%) 69 (37%) 53 (35%) 3 (18%)
 pCis 7 (1%) 0 (-) 3 (1%) 2 (1%) 2 (1%) 0 (-)
No of recurrences 0.337
 1 108 (51%) 18 (62%) 28 (46%) 33 (53%) 27 (52%) 2 (33%)
 2 46 (22%) 6 (21%) 16 (26%) 16 (26%) 6 (11%) 2 (33%)
 > 3 56 (27%) 5 (17%) 17 (28%) 13 (21%) 19 (37%) 2 (33%)
Smoking intensity 0.076
 1–9 cigarettes 128 (29%) NA 55 (30%) 23 (21%) 42 (34%) 8 (50%)
 10–19 cigarettes 140 (32%) NA 53 (28%) 42 (38%) 42 (34%) 3 (19%)
 >20 cigarettes 167 (38%) NA 78 (42%) 45 (41%) 39 (32%) 5 (31%)
Smoking duration < 0.001
 1–9 years 45 (10%) NA 26 (14%) 2 (2%) 16(14%) 1 (6%)
 10–19 years 83 (19%) NA 43 (23%) 10 (9%) 29 (25%) 1 (6%)
 20–29 years 87 (20%) NA 46 (25%) 12 (11%) 27 (23%) 2 (13%)
 30–39 years 88 (21%) NA 37 (20%) 28 (25%) 19 (16%) 4 (25%)
 > 40 years 127 (30%) NA 32 (17%) 60 (54%) 27 (23%) 8 (50%)
Smoking cessation 0.051
 < 20 years 48 (12%) NA 23 (9%) NA 25 (17%) NA
 21–40 years 208 (51%) NA 134 (51%) NA 74 (49%) NA
 > 40 years 155 (38%) NA 104 (40%) NA 51 (34%) NA
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For smoking duration, the HRs were divergent and did not 
indicate any trend (ptrend = 0.729) at all.
When considering multiple events that have occurred in 
patients (Table 4), the HRs are similar to the time-to-first 
recurrence analysis (HR for continuing vs. never smokers is 
1.10, 95% CI = 0.72–1.69). However, continuing smokers 
seemed to have experienced more recurrences than never 
smokers on average over 5 years on average, however not 
significantly (0.64 vs. 0.45, p = 0.308).
Discussion
Smoking cessation post‑diagnosis and BC 
recurrence and clinical implications
The reported HRs give reason to believe that quitting smok-
ing does not influence the likelihood of NMIBC recurrence 
over 5 years when compared to continuing smokers in our 
sample. However, the number of quitters in our prospec-
tive sample was small which complicates drawing conclu-
sions for this group. Another (retrospective) patient cohort 
study which assessed smoking cessation post-diagnosis 
concluded that quitting smoking significantly reduced risk 
of recurrence (HR 0.45, 95% CI 0.25–0.83, comparing 
quitters to continuing smokers); however, the proportion of 
quitters (~ 43% of current smokers at diagnosis) was also 
Table 2  Cox regression analysis investigating the association between combined smoking status, smoking cessation before diagnosis and passive 
smoking, and time-to-first recurrence in NMIBC patients treated with TURBT
*All estimates adjusted for age, sex, stage, grade, tumor size, and number of tumors
**Former smoker who started again and current smoker who quit smoking not included in former smokers at diagnosis
***Smokers who quit after their first event are considered as current smokers
****Reference category = current smokers at diagnosis, estimates also include former smokers who started again after diagnosis
Age and sex adjusted Multivariable model*
HR 95% CI Number of events/
patients at risk
HR 95% CI Number of 
events/patients 
at risk
Combined smoking status
 Never smoker 1.00 Ref. 29/103 1.00 Ref. 28/99
 Former smoker 0.79 0.51–1.24 61/266 0.78 0.48–1.24 59/254
 Continuing smoker 1.17 0.75–1.83 62/186 1.04 0.65–1.66 61/180
 Former smoker who started again** 1.04 0.65–1.64 51/150 0.87 0.53–1.41 49/146
 Current smoker who quit smoking*** 1.25 0.52-3.00 6/17 1.47 0.63–3.41 6/17
Smoking cessation (in years)****
 < 20 years 0.81 0.46–1.43 15/48 0.82 0.46–1.46 15/47
 21–40 years 0.76 0.53–1.08 57/208 0.74 0.51–1.08 54/200
 > 40 years 0.67 0.44–1.02 39/155 0.71 0.46–1.09 38/148
p for trend 0.070 0.126
Exposed to passive smoking during childhood?
 No 1.00 Ref. 36/142 1.00 Ref. 35/138
 Yes 1.23 0.86–1.75 173/576 1.17 0.81–1.68 168/554
Exposed to passive smoking during adulthood?
 No 1.00 Ref. 74/261 1.00 Ref. 74/261
 Yes 1.03 0.77–1.38 135/454 1.02 0.76–1.36 135/454
Fig. 1  Cumulative incidence functions with correction for competing 
risk (death) indicating cumulative incidence of first recurrence per 
category of smoking status in NMIBC patients treated with TURBT
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considerably larger [14]. In another retrospective cohort 
study, Fleshner et al. concluded that it remained unclear 
whether smoking cessation at time of diagnosis is benefi-
cial with regard to BC recurrence [15] although Aveyard 
et al. estimated that the Fleshner study shows a HR of 0.71 
(95% CI 0.48–1.05) when comparing quitters to continuing 
smokers [26], which is similar to the estimate observed in 
the study by Chen et al. Taken together, the limited evidence 
at this point seems to indicate that quitting smoking at or 
closely after diagnosis could reduce risk of recurrence. How-
ever, even across several smoking-related cancer sites such 
as lung cancer where this association is stronger, evidence to 
imply a strong, causal relationship between smoking behav-
ior after diagnosis and recurrence is still limited [27]; so 
more prospective research is needed.
Considering the prolonged latency period for the develop-
ment of BC after exposures [2], it is credible that the asso-
ciation between altering smoking behavior post-diagnosis 
and likelihood of a first recurrence or multiple recurrences 
over 5 years is not as strong as the association between 
smoking and carcinogenesis. Similarly, epidemiological 
evidence suggests that pre-diagnostic smoking cessation 
Table 3  Multivariable Cox 
regression analysis concerning 
the association between 
smoking pack-years, intensity, 
and duration (recorded at 
diagnosis) with time-to-first 
recurrence in NMIBC patients 
treated with TURBT
*All estimates adjusted for age, sex, stage, grade, tumor size, and number of tumors at diagnosis
Age and sex adjusted Multivariable model*
HR 95% CI Number of events/
patients at risk
HR 95% CI Number of 
events/patients 
at risk
Never smoker 1.00 Ref. 29/103 1.00 Ref. 28/99
Pack-years
 1–9 pack-years 0.86 0.53–1.42 36/141 0.81 0.48–1.37 34/134
 10–19 pack-years 0.95 0.54–1.67 22/81 0.92 0.51–1.65 22/80
 20–29 pack-years 0.93 0.49–1.77 15/58 0.81 0.42–1.60 15/57
 30–39 pack-years 0.70 0.35–1.43 11/55 0.60 0.30–1.22 11/53
 > 40 pack-years 1.28 0.76–2.14 30/86 1.14 0.66–1.97 29/83
p for trend 0.365 0.688
Smoking intensity (cigarettes/day)
 1–9 cigarettes 0.83 0.50–1.38 32/128 0.81 0.47–1.38 30/122
 10–19 cigarettes 0.75 0.45–1.28 31/140 0.61 0.35–1.07 31/138
 20+ cigarettes 1.24 0.79–1.96 55/167 1.16 0.72–1.85 54/160
p for trend 0.112 0.198
Smoking duration (in years)
 1–9 years 1.03 0.52–2.05 12/45 0.97 0.48–1.95 12/43
 10–19 years 0.94 0.54–1.62 22/83 0.85 0.48–1.50 21/78
 20–29 years 0.79 0.45–1.39 21/87 0.79 0.44–1.44 20/85
 30–39 years 1.08 0.61–1.89 26/88 0.93 0.52–1.66 25/85
 40+ years 1.00 0.60–1.64 36/127 0.88 0.52–1.49 36/124
p for trend 0.917 0.729
Table 4  Conditional risk 
set model investigating time 
between multiple recurrence 
events in NMIBC patients 
treated with TURBT by 
smoking status at diagnosis and 
after diagnosis
*All estimates adjusted for age, sex, stage, grade, tumor size, number of tumors, and re-resection of recur-
rent tumor
**Smokers who have quit after their first event (n = 2) are also included
HR* 95% CI Number of 
events/patients 
at risk
Mean number of recur-
rences over 5 years (95% 
CI)
Smoking status
 Never smoker 1.00 Ref. 43/99 0.45 (0.28–0.63)
 Former smoker 0.71 0.47–1.08 108/254 0.45 (0.33–0.57)
 Continuing smoker 1.10 0.72–1.69 116/180 0.64 (0.47–0.81)
 Former smoker who started again 0.89 0.56–1.43 108/146 0.82 (0.57–1.06)
 Current smoker who quit smoking** 0.85 0.35–2.04 18/19 0.84 (0.10–1.58)
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does not immediately lower the risk of BC [28], also indi-
cating a longer latency period than 5 years. Furthermore, it 
is considered that a first BC recurrence is often the result of 
incomplete resection and/or tumor cell re-implantation, and 
that genuine new tumor formation only plays a more impor-
tant role in later recurrences [29]. It is therefore reasonable 
to suggest that, because of the DNA-damaging effects of 
cigarette smoke [30], modifying smoking behavior may only 
influence later recurrences and possibly those that may occur 
beyond the follow-up period of 5 years reported here.
Notwithstanding the results from our study, when consid-
ering the impact of comorbidities on overall survival in BC 
patients [31] which include several smoking-related diseases 
[32] and other evidence indicating beneficial and significant 
results of post-diagnostic smoking cessation in retrospective 
studies [14, 15], it is evident that smoking cessation should 
be encouraged for NMIBC patients at diagnosis.
It is striking that only 14% of current smokers at diag-
nosis in our sample quit smoking post-diagnosis. There are 
examples of successful smoking cessation interventions in 
urology [33], and several studies found that when patients 
were diagnosed with BC they were more likely to quit 
smoking [34, 35]. Therefore, urologists should continue to 
improve smoking cessation counseling in newly diagnosed 
NMIBC patients and be updated on the available tools to 
improve smoking cessation figures. Moreover, more inter-
vention clinical research investigating smoking cessation 
programmes in NMIBC patients is warranted.
Smoking behavior pre‑diagnosis and exposure 
to environmental tobacco smoke
Smoking cessation was most beneficial, with regard to 
reducing the risk of recurrence, the longer before diagnosis 
it happened compared to continuing smokers. This was the 
strongest association observed in our study and has been 
observed in other studies as well, although not consistently 
[12]. Other results were in line with earlier studies inves-
tigating smoking status at diagnosis and BC recurrence as 
well, by indicating a slightly increased risk of recurrence 
in NMIBC patients for current smokers compared to never 
smokers in a meta-analysis [10].
Another recent study not included in the aforemen-
tioned meta-analysis shows similar HRs (HR 1.49, 95% 
CI 0.95–2.33) for current smokers at diagnosis [8]. How-
ever, when including this study and our study (data from 
continuing smokers) in the meta-analysis, the pooled HR 
barely changes from 1.27 (95% CI 1.09–1.46) to 1.26 (95% 
CI 1.12–1.40) [10], indicating a significantly increased risk 
of recurrence for current smokers at diagnosis compared to 
never smokers. Possibly, the lack of association for continu-
ing smokers in this study can be explained through multiple 
synchronous tumors being present at diagnosis in epithelial 
tumors. This theory of “field cancerization” proposes that 
(pre-)malignant transformation of cells has already occurred 
at different sites across the urothelium, explaining why 
(changing) smoking exposure will not have a large impact 
on disease prognosis [36].
Additionally, given that recent reviews indicate no con-
siderable heterogeneity between studies that do not show an 
association between environmental tobacco smoke and risk 
of BC, it is unlikely that we would have shown any substan-
tial association with BC recurrence either [37, 38].
Because no substantial association between smoking 
status pre-diagnosis and BC recurrence was observed in 
adjusted models it is possible that the tumor characteristics 
associated with BC recurrence (stage, grade, tumor size, 
number of tumors) included as confounders in these models 
overshadow the effects of smoking behavior in determining 
risk of BC recurrence [21] and possible also mortality since 
no association between quitting smoking after diagnosis and 
all-cause or bladder cancer-specific mortality was observed 
in a large retrospective cohort study [16]. Moreover, since 
current smokers at diagnosis in our cohort have been asso-
ciated with having a higher stage, higher grade, and larger 
tumor size compared to never smokers [39], smoking behav-
ior might play a more crucial role in determining risk of 
recurrence already before diagnosis through promoting unfa-
vorable tumor characteristics associated with BC recurrence 
at diagnosis, although in a Dutch cohort of 323 UBC patients 
there was only a weak association between smoking inten-
sity and increased risk of a more aggressive tumor type [40].
Strengths and weaknesses
Despite the prospective nature of our study there were some 
limitations restricting the analyses. Due to the relatively 
short follow-up of this study, long-term effects of smoking 
cessation post-diagnosis could not be assessed and the num-
ber of deaths due to BC in the NMIBC patients within our 
cohort was too low for Cox regression analysis. Also, it was 
not possible to obtain detailed information on adjuvant ther-
apy for all patients, so differences in adjuvant therapy could 
not be considered in the statistical analysis. Additionally, 
we did not correct for biomarkers of BC recurrence such as 
mutations in the FGFR3 or TP53 genes [41], although they 
might work together with smoking intensity in predicting 
BC outcome [42].
Furthermore, one of the caveats of using only self-
reported questionnaire data to assess smoking exposure 
was likely demonstrated in our sample of NMIBC patients. 
The large proportion (about 1 in 3) of former smokers pre-
diagnosis who reported to have started smoking again post-
diagnosis is implausible and is probably observed due to 
misclassification of either the questionnaire at baseline or 
during follow-up. A high misclassification rate (47%) when 
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comparing self-reported data on smoking behavior to coti-
nine values in blood was also shown in another sample of 
bladder cancer patients undergoing surveillance [43]. Prefer-
ably, future studies should consider more reliable ways of 
verifying smoking exposure through biochemical analysis.
Unfortunately, at the start of the study we did not antici-
pate this small proportion of quitters after diagnosis which 
is why the analysis concerning quitters is underpowered.
Conclusion
Although quitting smoking after diagnosis might reduce 
probability of recurrence based on retrospective evidence, 
the number of NMIBC patients quitting smoking in our pro-
spective study was low. This indicates an important role for 
urologists and other health care professionals in promoting 
smoking cessation in NMIBC. Based on the current evi-
dence, smoking cessation pre-diagnosis seems to have the 
largest impact on reducing risk of recurrence after NMIBC 
diagnosis.
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